WO2006103356A2 - Use of compounds inducing synthesis of sirt proteins in or for preparing a cosmetic or pharmaceutical composition - Google Patents

Use of compounds inducing synthesis of sirt proteins in or for preparing a cosmetic or pharmaceutical composition Download PDF

Info

Publication number
WO2006103356A2
WO2006103356A2 PCT/FR2006/000699 FR2006000699W WO2006103356A2 WO 2006103356 A2 WO2006103356 A2 WO 2006103356A2 FR 2006000699 W FR2006000699 W FR 2006000699W WO 2006103356 A2 WO2006103356 A2 WO 2006103356A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
skin
proteins
compound
peptide
Prior art date
Application number
PCT/FR2006/000699
Other languages
French (fr)
Other versions
WO2006103356A3 (en
Inventor
Claude Dal Farra
Nouha Domloge
Jean-Marie Botto
Original Assignee
Societe D'extraction Des Principes Actifs Sa (Vincience)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe D'extraction Des Principes Actifs Sa (Vincience) filed Critical Societe D'extraction Des Principes Actifs Sa (Vincience)
Publication of WO2006103356A2 publication Critical patent/WO2006103356A2/en
Publication of WO2006103356A3 publication Critical patent/WO2006103356A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70Biological properties of the composition as a whole

Definitions

  • the invention relates to the field of cosmetics and pharmaceuticals, particularly the field of dermatology.
  • the subject of the present invention is a cosmetic or dermopharmacological or dermatological composition comprising, as active agent, in a cosmetically or pharmaceutically acceptable medium, at least one compound capable of activating the synthesis of SIRT proteins in the cells of the skin.
  • the present invention also relates to the use of said composition.
  • the skin is a covering organ covering the entire surface of the body. It is a vital organ providing multiple functions such as sensory functions, protective against multiple external attacks, immune, metabolic or thermoregulatory. These roles are made possible by a complex structure that combines various tissue structures.
  • the skin, as well as the integuments, are subjected constantly to nuisances of external origin which appear in different aspects. These aggressions can be important and they can threaten the balance and appearance of the skin. By way of example, mention may be made of visible or ultraviolet radiation, atmospheric pollutants, chemical products, stresses of mechanical origin, viral or bacterial infections, etc.
  • the skin is our first barrier against the external environment, however this barrier is not always sufficient and these attacks can have many harmful consequences for the body, both at this level and at the cellular level.
  • the cells of the skin in direct contact with the external environment, experience a lot of damage, including an alteration of their macromolecules. For example, damage to DNA (such as double or single-strand breaks, mutations, etc.), proteins (carbonylation of proteins, etc.), fatty acid modifications (lipid peroxidation). ...) resulting in damage to the cell membranes and an alteration of the skin barrier.
  • SIRT protein and more specifically the SIRT1 protein, was expressed in the cells of the skin and that its expression was related to the various stresses that cutaneous cells encounter. They have notably demonstrated that the induction of the expression of this protein, by different agents, made it possible to protect the cells and to better help them fight against the stress and the intrinsic aging thereof.
  • SIRT proteins are part of the Sirtuine family, they are nuclear proteins, NAD + dependent, playing an important role in the deacetylation of histones.
  • SIR Stress Information Regulators
  • SIRT1 protein is the most well-characterized human sirtuin, interacting with many transcriptional regulators.
  • the human protein SIRT1 has been described as being involved in the regulation of p53 (Cheng HL et al., Proc Natl Acad Sci US A 2003), and, more recently, as a modulator of cellular senescence (Langley E and Al, EMBO J. 2002).
  • Other Sir human proteins have been discovered (SIRT2, SIRT3, SIRT4-7).
  • SIRT2 has been little studied, but some studies have demonstrated its role in the control of mitotic activity (Dryden SC and Al, Mol CeIl Biol 2003) and its involvement in the regulation of the p53 protein (Vaziri H and Al, CeIl 2001).
  • sirtuin deacetylases are considered to be an enzyme family that plays an important role in the regulation of cell death and in its life cycle (M. and Chiarugi A., Tr ends Pharmacol ScL, 2005) .
  • the present invention relates to a cosmetic or pharmaceutical composition containing, in a cosmetically or pharmaceutically acceptable medium, at least one compound capable of activating the synthesis of SIRT proteins in the cells of the skin.
  • the compounds will activate a particular class of SIRT proteins, SIRT1 proteins.
  • compound capable of activating the synthesis of SIRT proteins in the cells of the skin is meant essentially all compounds capable of promoting the endogenous production of SIRT proteins; and most particularly the molecules involved in the positive control of precursors such as DNA or RNA.
  • trans-stilbene derivatives resveratrol, piceatannol
  • chalcone derivatives isoliquiritigenin, butene
  • flavone derivatives flavone derivatives
  • the compounds capable of promoting the synthesis of SIRT proteins in the cells of the skin will be compounds of a peptide nature.
  • peptide fragments are peptide fragments whose number of amino acids is between 3 and 50, more particularly between 3 and 10. All these peptide fragments have a biological activity.
  • the compound capable of activating the synthesis of the SIRT proteins of the skin is a peptide of formula (I):
  • the compound, a SIRT protein inducer of the skin possesses the Thr-GIn-Asn-Ile-Asp-Thr-Leu sequence.
  • SIRT proteins of the skin are meant all the proteins of the SIRT family, but preferentially, the term SIRT1 proteins is meant.
  • variants refers to a polypeptide or peptide that differs from, for example, the sequence of a reference peptide while retaining its essential properties. Generally, the differences are limited so that the sequences of the reference peptide and those of the variant are quite similar and, in some regions, identical.
  • a variant peptide and a reference peptide may thus differ from the amino acid sequence by one or more substitutions, additions, deletions in all combinations.
  • the variant forms are those which vary from the reference sequences, by the substitution of chemically equivalent amino acids
  • substitutions are between Ala, Val, Leu and Ile; between Ser and Thr; between Asp and Glu acid residues; between Asn and GIn; and between the basic residues Lys and Arg; or between the aromatic residues Phe and Tyr.
  • amino acid refers herein to any natural or unnatural organic acid having the formula:
  • each -R is independently selected from hydrogen and an alkyl group having 1 to 12 carbon atoms.
  • at least one -R group of each amino acid is a hydrogen.
  • alkyl is meant herein a carbon chain which may be linear or branched, substituted (mono- or poly-) or unsubstituted ; saturated, mono-saturated (a double or triple bond in the chain) or polyunsaturated (two or more double bonds, two or more triple bonds, one or more double bonds and one or more triple bonds in the chain).
  • peptide refers to a sequence of two or more amino acids linked together by peptide bonds or modified peptide bonds; a polypeptide designating a larger peptide.
  • peptide is meant the natural or synthetic peptide of the invention as described above or at least one of its fragments, whether obtained by proteolysis or synthetically or any natural or synthetic peptide which the sequence is totally or partially constituted by the sequence of the peptide previously described.
  • the invention relates to a use as defined above characterized in that the peptide is in protected form or not.
  • protection based on either acylation or acetylation of the amino-terminus, or amidation or esterification of the carboxy terminus, or both is used.
  • amino acid derivatives and the peptide derivatives also relate to amino acids and peptides linked together by a pseudo-peptide bond.
  • pseudo-peptide bond means all types of bonds likely to replace the "conventional" peptide bonds.
  • the amino acids constituting the peptide according to the invention can be in L- and D- configuration; preferably, the amino acids are in L form.
  • the peptide according to the invention can therefore be in L-, D- or DL- form.
  • the peptides according to the invention can be prepared by any appropriate method, thus the peptides can be peptides isolated from naturally occurring peptides and proteins, recombinant peptides, synthetic peptides, or peptides produced by a combination of these methods.
  • the methods for preparing the peptides according to the invention are well known to those skilled in the art.
  • the peptide according to the invention may be a peptide of natural or synthetic origin.
  • the peptide is obtained by chemical synthesis.
  • compounds capable of activating the synthesis of SIRT proteins in skin cells may be used alone or in combination with at least one other active agent, in or for the preparation of a cosmetic composition and or dermatological and / or pharmaceutical.
  • the abovementioned compounds, according to the invention are previously solubilized in one or more cosmetically or pharmaceutically acceptable solvents, conventionally used by those skilled in the art, such as water or ethanol.
  • solvents conventionally used by those skilled in the art, such as water or ethanol.
  • the abovementioned compounds are first solubilized in a cosmetic or pharmaceutical vector such as liposomes or adsorbed on powdery organic polymers, mineral supports such as talcs and bentonites, and more generally solubilized in or attached to any cosmetically or pharmaceutically acceptable carrier.
  • a cosmetic or pharmaceutical vector such as liposomes or adsorbed on powdery organic polymers, mineral supports such as talcs and bentonites, and more generally solubilized in or attached to any cosmetically or pharmaceutically acceptable carrier.
  • composition containing compounds capable of activating the synthesis of SIRT proteins in skin cells, can be a dermatological or pharmaceutical or cosmetic composition.
  • composition according to the invention is preferably a cosmetic and / or dermatological composition, the excipients of which are suitable for administration by the route external topical; this composition advantageously comprising a cosmetically or pharmaceutically acceptable medium.
  • the composition is a cosmetic composition, because it is intended to improve the appearance and general cutaneous performance of the individual who makes use of it.
  • the effective amount of active ingredient is the amount needed to achieve the desired result.
  • the abovementioned compounds are present in the compositions of the invention in an amount representing between 10 -6 and 20%, approximately, and preferentially in an amount representing between 10 -4 and 5 About one percent of the total weight of the final composition
  • the peptide will be present in the compositions of the invention at a concentration of between 0.005 and 500 ppm ( parts per million), and preferably at a concentration of between 0.1 and 50 ppm approximately relative to the total weight of the final composition, whatever the form of the invention, the composition according to the invention can be injected or applied to the skin (on any cutaneous zone of the body), the hair, the nails or the mucous membranes
  • the composition according to the invention may be s all galenic forms normally used.
  • compositions according to the present invention will be in a dosage form suitable for topical administration to the skin, and cover all cosmetic or dermatological forms.
  • These compositions must therefore contain a cosmetically acceptable medium, that is to say, compatible with the skin, mucous membranes and integuments.
  • compositions may especially be in the form of an aqueous solution, hydroalcoholic or oily; an oil-in-water, water-in-oil emulsion or multiple emulsions; they may also be in the form of creams, suspensions or powders, suitable for application to the skin, mucous membranes, lips and / or integuments.
  • These compositions may be more or less fluid and have the appearance of a cream, lotion, milk, serum, ointment, gel, paste or paste. a foam. They can also be in solid form, as a stick or be applied to the skin in aerosol form. They can be used as a care product and / or as a make-up product for the skin.
  • compositions additionally comprise any additive commonly used in the field of application envisaged as well as the adjuvants necessary for their formulation, such as solvents, thickeners, diluents, antioxidants, dyes, sunscreens, self-tanning agents, pigments, fillers, preservatives, perfumes, odor absorbers, cosmetic or pharmaceutical active ingredients, essential oils, vitamins, essential fatty acids, surfactants, film-forming polymers, etc. .
  • additives such as solvents, thickeners, diluents, antioxidants, dyes, sunscreens, self-tanning agents, pigments, fillers, preservatives, perfumes, odor absorbers, cosmetic or pharmaceutical active ingredients, essential oils, vitamins, essential fatty acids, surfactants, film-forming polymers, etc.
  • these adjuvants and their proportions are chosen in such a way as not to harm the desirable advantageous properties of the composition according to the invention.
  • These adjuvants may, for example, correspond to 0.01 to 20% of the total weight of the composition.
  • the fatty phase may represent from 5 to 80% by weight and preferably from 5 to 50% by weight relative to the total weight of the composition.
  • the emulsifiers and co-emulsifiers used in the composition will be chosen from those conventionally used in the field under consideration. For example, they can be used in a proportion ranging from 0.3 to 30% by weight, relative to the total weight of the composition.
  • compositions according to the invention find an application in particular as cosmetic or pharmaceutical compositions for the skin, mucous membranes and / or semi-mucous membranes. They find application as a protection product and / or skincare, or as an anti-wrinkle and / or anti-aging composition. It is also possible to envisage other applications in the field of compositions in combination, for example with other active agents.
  • the compounds according to the invention can also be used in cosmetic compositions for body and hair hygiene.
  • SIRT1 protein has a very important function in aging and cellular protection. Indeed, it has been shown that an increase in its expression allows the skin to better withstand the stress that surrounds it, that is to say to better fight against the phenomena of oxidation and, more generally, of better fight against aging. More generally, the induction of the expression of this protein in skin cells provides a general improvement of cell protection mechanisms and would increase the cell life.
  • an essential aspect of the invention is the use of at least one inducing compound for the endogenous synthesis of SIRT proteins in skin cells, in or for the preparation of a cosmetic and / or pharmaceutical composition, the compound or the composition containing it being intended to provide care to the skin and / or integuments. More precisely among the compounds inducing the endogenous synthesis of proteins
  • SIRT 5 may be compounds of peptide nature.
  • the compounds capable of promoting the synthesis of SIRT proteins, and more particularly of SIRT1 proteins will be peptides corresponding to formula (I).
  • the SIRT protein inducing compound of the skin has the Thr - GIn - Asn - Ile - Asp - Thr - Leu sequence.
  • Said compounds being also advantageously used in order to fight in a curative and / or preventive manner against the manifestations of skin aging, but also in order to improve the appearance of the skin and / or integuments.
  • the care of the skin and / or integuments we mean all the actions intended to maintain or restore a good functioning of the skin and / or superficial body growths or any means which serves to preserve or improve their appearance and / or their appearance. So the care includes hydration, soothing, protection against all types of aggression, including sun protection, the fight and the prevention of the manifestations of aging.
  • cutaneous manifestations of aging is meant any changes in the external appearance of the skin due to aging, such as, for example, wrinkles and fine lines, wilted skin, soft skin, thinned skin, lack of elasticity and / or skin tone, dull and lackluster skin but also any internal changes in the skin that do not always translate into an external appearance modified, for example, any internal skin damage resulting from exposure to ultraviolet radiation.
  • improved the appearance of the skin means all phenomena that are likely to result in a visual improvement of the state of the skin. The skin will look better; it will be, for example, much more beautiful, firm and / or smooth. All small imperfections will be diminished or removed. The papery appearance of the skin will, for example, be attenuated.
  • the active ingredient according to the invention may be intended to protect keratinous substrates, and more particularly to protect the skin and / or integuments against all types of external aggression.
  • the use of these active agents, or a composition containing them will allow the keratinous substrates to be protected and to better withstand the stress that the environment produces on them.
  • the term "external aggression” is understood to mean the aggressions that the environment can produce. These attacks can be of chemical, physical, biological or thermal origin.
  • the compounds will be advantageously used to reduce and / or prevent inflammatory and / or skin irritant reactions.
  • the compounds according to the invention intended to activate the endogenous synthesis of SIRT1 proteins, have anti-inflammatory and anti-irritant effects.
  • the use of the properties of these assets therefore makes it possible to have a skin that is more protected and much less sensitive to the various aggressions that it may encounter. The skin is soothed.
  • the compounds according to the invention stimulate the metabolic functioning of the cells of the skin. They thus make it possible to increase the synthesis of proteins essential to its functioning, in particular by increasing the synthesis of proteins constituting the extracellular matrix.
  • the compounds according to the invention, or the composition containing them thus have a positive action on tissue regeneration.
  • the compounds according to the invention are particularly effective in treating cicatrization disorders.
  • SIRT proteins are thus used in or for the manufacture of a pharmaceutical and / or cosmetic composition, for topical use. They will be used, more generally, to treat dermatological conditions.
  • Dermatological conditions are all diseases affecting the skin and having or not visible consequences. As such, for example: disorders related to cell differentiation and proliferation problems, problems with keratinization, inflammatory or allergic disorders, disorders related to sebaceous functions, dermal or epidermal proliferations (benign or malignant); cutaneous disorders due to exposure to UV radiation, pathologies associated with chronological or actinic aging.
  • the compounds according to the invention intended to activate the endogenous synthesis of SIRT proteins in the cells of the skin, will be used for the manufacture of a medicament intended for the treatment of affections dermal.
  • the present invention also relates to the use, as a medicament, of the compounds described above.
  • the present invention relates to a cosmetic treatment method for care of the skin and / or superficial body growth consisting in applying to the surface of the skin an effective quantity of active agent, or of the cosmetic composition containing it, as defined above, in order to obtain the desired action.
  • These methods may especially be used in order to preventatively and / or curatively treat the manifestations of cutaneous aging, but also in order to protect the skin and / or integuments against external aggressions such as the harmful effects of radiation, in particular UV radiation. or to fight against the manifestations of inflammation and skin irritation.
  • the cosmetic treatment method of the invention may be implemented in particular by applying the cosmetic compositions as defined above, according to the usual technique of use of these compositions, for example: application of creams, gels, serums , lotions, milks, shampoos or sunscreens, on the skin or on the hair, or application of toothpaste on the gums.
  • phase A and phase B are heated separately at a temperature between 65 ° C and 70 ° C, phase C is incorporated, then phase A is emulsified in phase B.
  • the carbomer is neutralized with the phase D at a temperature around 45 ° C.
  • Phase E is then added with stirring and cooling is continued to 25 ° C.
  • phase A and phase B are heated separately at a temperature between 70 ° C and 75 ° C.
  • Phase B is emulsified in A with stirring "Staro". After cooling to 50 ° C, the mixture is neutralized with phase C.
  • Phase D is then added when the temperature is below 40 ° C. Cooling is continued to 25 0 C with slow stirring.
  • phase A and phase B are heated separately at a temperature between 70 ° C and 75 ° C.
  • Phase B is emulsified in A with stirring.
  • Phase C is added at 45 ° C, increasing stirring.
  • Phase D is then added when the temperature is below 40 ° C. Cooling is continued up to 25 ° C with vigorous stirring.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention concerns a cosmetic or dermopharmaceutical or dermatological composition comprising, as active principle, in a cosmetically or pharmaceutically acceptable medium, at least one compound capable of activating the synthesis of SIRT proteins in the skin cells. The invention also concerns the use of said compositions.

Description

UTILISATION DE COMPOSES INDUCTEURS DE LA SYNTHESE DES PROTEINES SIRT DANS OU POUR LA PREPARATION D'UNE COMPOSITION COSMETIQUE OU PHARMACEUTIQUE. USE OF INDUCING COMPOUNDS OF SYNTHESIS OF SIRT PROTEINS IN OR FOR THE PREPARATION OF A COSMETIC OR PHARMACEUTICAL COMPOSITION.
L'invention concerne le domaine de la cosmétique et de la pharmaceutique, notamment le domaine de la dermatologie. La présente invention a pour objet une composition cosmétique ou dermo-pharmaceutique ou dermatologique comprenant, en tant qu'agent actif, dans un milieu cosmétiquement ou pharmaceutiquement acceptable, au moins un composé susceptible d'activer la synthèse des protéines SIRT dans les cellules de la peau. La présente invention a aussi pour objet l'utilisation de ladite composition.The invention relates to the field of cosmetics and pharmaceuticals, particularly the field of dermatology. The subject of the present invention is a cosmetic or dermopharmacological or dermatological composition comprising, as active agent, in a cosmetically or pharmaceutically acceptable medium, at least one compound capable of activating the synthesis of SIRT proteins in the cells of the skin. The present invention also relates to the use of said composition.
La peau est un organe de revêtement recouvrant la totalité de la surface du corps. C'est un organe vital assurant des fonctions multiples telles que des fonctions sensitives, protectrices vis-à-vis d'agressions externes multiples, immunitaires, métaboliques ou encore thermorégulatrices. Ces rôles sont rendus possibles grâce à une structure complexe qui associe des structures tissulaires variées. La peau, ainsi que les phanères, sont soumis constamment à des nuisances d'origine extérieure qui se manifestent sous différents aspects. Ces agressions peuvent être importantes et elles peuvent menacer l'équilibre et l'aspect de la peau. A titre d'exemple, on peut citer les rayonnements visibles ou ultraviolets, les polluants atmosphériques, les produits chimiques, les stress d'origines mécaniques, les infections virales ou bactériennes...The skin is a covering organ covering the entire surface of the body. It is a vital organ providing multiple functions such as sensory functions, protective against multiple external attacks, immune, metabolic or thermoregulatory. These roles are made possible by a complex structure that combines various tissue structures. The skin, as well as the integuments, are subjected constantly to nuisances of external origin which appear in different aspects. These aggressions can be important and they can threaten the balance and appearance of the skin. By way of example, mention may be made of visible or ultraviolet radiation, atmospheric pollutants, chemical products, stresses of mechanical origin, viral or bacterial infections, etc.
La peau est notre première barrière contre l'environnement extérieur, cependant cette barrière n'est pas toujours suffisante et ces agressions peuvent avoir de nombreuses conséquences néfastes pour l'organisme, tant au niveau de celui-ci qu'au niveau cellulaire. Les cellules de la peau, en contact direct avec le milieu extérieur, connaissent de nombreux dommages, notamment une altération de leurs macromolécules. On peut citer, par exemple, les dommages occasionnés à l'ADN (tels que des coupures double ou simple brin, des mutations...), aux protéines (carbonylation des protéines...), modifications des acides gras (péroxydation des lipides...) ayant comme conséquence des dommages au niveau des membranes cellulaires et une altération de la barrière cutanée.The skin is our first barrier against the external environment, however this barrier is not always sufficient and these attacks can have many harmful consequences for the body, both at this level and at the cellular level. The cells of the skin, in direct contact with the external environment, experience a lot of damage, including an alteration of their macromolecules. For example, damage to DNA (such as double or single-strand breaks, mutations, etc.), proteins (carbonylation of proteins, etc.), fatty acid modifications (lipid peroxidation). ...) resulting in damage to the cell membranes and an alteration of the skin barrier.
Ces altérations ont lieu sur tous types cellulaires cutanés, mais on peut citer en particulier : les kératinocytes, les fibroblastes et les mélanocytes. Ces agressions extérieures ont souvent comme conséquence visible un vieillissement prématuré au niveau de la peau, une dépigmentation, des phénomènes d'inflammation. Ils peuvent même parfois aboutir à des processus de cancérisation et à des phénomènes de nécrose des tissus. Il est donc important de mettre au point des systèmes capables de lutter activement contre ces agressions et leurs conséquences. La recherche de moyens afin de préserver la peau et les phanères, voire de les protéger contre toutes manifestations susceptibles d'altérer leur bon fonctionnement ou leur aspect, mobilise un très grand nombre de chercheurs, notamment dans le domaine des cosmétiques.These alterations take place on all cutaneous cell types, but there may be mentioned in particular: keratinocytes, fibroblasts and melanocytes. These external aggressions often result in premature aging at the level of skin, depigmentation, inflammation phenomena. They can even sometimes lead to cancer processes and tissue necrosis. It is therefore important to develop systems capable of actively combating these attacks and their consequences. The search for ways to preserve the skin and integuments, or even protect them against all manifestations that could affect their functioning or appearance, mobilizes a very large number of researchers, particularly in the field of cosmetics.
Les professionnels de la santé et de la cosmétique sont donc en permanence à la recherche de principes actifs performants, réellement efficaces et ayant un large spectre d'action. De plus, ces actifs se doivent d'avoir une forte compatibilité dermatologique de façon à ce que chez tous les utilisateurs, même les plus sensibles, il n'y ait aucune réaction d'irritation. Il subsiste donc le besoin de développer des actifs dermatologiques et/ou cosmétiques ayant une très bonne efficacité ainsi qu'un large spectre d'action au niveau de la peau et des phanères. Or, les demandeurs ont récemment découvert l'implication d'une nouvelle protéine dans les mécanismes des cellules de la peau qui possède un rôle important dans le vieillissement et la protection cellulaire.Health and cosmetic professionals are therefore constantly looking for active ingredients that are effective, truly effective and have a broad spectrum of action. In addition, these assets must have a high dermatological compatibility so that all users, even the most sensitive, there is no irritation reaction. There is therefore still a need to develop dermatological and / or cosmetic active agents that have a very good efficacy as well as a broad spectrum of action on the skin and integuments. Now, applicants have recently discovered the involvement of a new protein in the mechanisms of skin cells that has an important role in aging and cell protection.
Ils ont en effet démontré que la protéine SIRT, et plus précisément la protéine SIRTl, était exprimée dans les cellules de la peau et que son expression était en relation avec les différents stress que rencontrent les cellules cutanées. Ils ont notamment démontré que l'induction de l'expression de cette protéine, par différents agents, permettait de protéger les cellules et de mieux les aider à lutter contre le stress et le vieillissement intrinsèque de celles-ci.They have indeed demonstrated that the SIRT protein, and more specifically the SIRT1 protein, was expressed in the cells of the skin and that its expression was related to the various stresses that cutaneous cells encounter. They have notably demonstrated that the induction of the expression of this protein, by different agents, made it possible to protect the cells and to better help them fight against the stress and the intrinsic aging thereof.
Les protéines SIRT font partie de la famille des Sirtuines, ce sont des protéines nucléaires, NAD+ dépendantes, jouant un rôle important dans la désacétylation des histones. Les gènes SIR (Silent Information Régulators), codant pour les protéines SER, ont pour la première fois été décrits chez S. cerevisiae en 1979 (Rine J et AL, GeneticsSIRT proteins are part of the Sirtuine family, they are nuclear proteins, NAD + dependent, playing an important role in the deacetylation of histones. SIR (Silent Information Regulators) genes, encoding SER proteins, were first described in S. cerevisiae in 1979 (Rine J and AL, Genetics
1979). Plus tard, il a été démontré qu'une surexpression de la protéine SIR2P, chez C. elegans, permettait d'augmenter la durée de vie de cet organisme (Tissenbaum et AL, Nature 2001). Cette étude émettant ainsi l'hypothèse selon laquelle ces protéines seraient liées à la longévité.1979). Later, it was shown that overexpression of the protein SIR2P, in C. elegans, allowed to increase the life of this organism (Tissenbaum and AL, Nature 2001). This study thus emits the hypothesis that these proteins are linked to longevity.
La protéine SIRTl est la sirtuine humaine la mieux caractérisée, interagissant avec de nombreux régulateurs de la transcription. La protéine humaine SIRTl a été décrite comme étant impliquée dans la régulation de p53 (Cheng HL et Al. Proc Natl Acad Sci U S A. 2003), et, plus récemment, comme un modulateur de la sénescence cellulaire (Langley E et Al, EMBO J. 2002). D'autres protéines humaines Sir ont été découvertes (SIRT2, SIRT3, SIRT4-7). La protéine humaine SIRT2 a été peu étudiée, quelques études ont cependant démontré son rôle dans le contrôle de l'activité mitotique (Dryden SC et Al, Mol CeIl Biol. 2003) ainsi que son implication dans la régulation de la protéine p53 (Vaziri H et Al, CeIl. 2001). A ce jour, les sirtuines désacétylases sont considérées comme une famille d'enzymes occupant un rôle important dans la régulation de la mort cellulaire et dans son cycle de vie (P or eu M. and Chiarugi A., Tr ends Pharmacol ScL, 2005). La présente invention se rapporte à une composition cosmétique ou pharmaceutique contenant, dans un milieu cosmétiquement ou pharmaceutiquement acceptable, au moins un composé susceptible d'activer la synthèse des protéines SIRT dans les cellules de la peau. Préférentiellement selon l'invention, les composés activeront une classe de protéines SIRT particulière, les protéines SIRTl. A ce jour, aucune utilisation de composés inducteurs de synthèse de protéines de la famille des SIRT, dans les cellules de la peau, n'a été décrite.SIRT1 protein is the most well-characterized human sirtuin, interacting with many transcriptional regulators. The human protein SIRT1 has been described as being involved in the regulation of p53 (Cheng HL et al., Proc Natl Acad Sci US A 2003), and, more recently, as a modulator of cellular senescence (Langley E and Al, EMBO J. 2002). Other Sir human proteins have been discovered (SIRT2, SIRT3, SIRT4-7). The human protein SIRT2 has been little studied, but some studies have demonstrated its role in the control of mitotic activity (Dryden SC and Al, Mol CeIl Biol 2003) and its involvement in the regulation of the p53 protein (Vaziri H and Al, CeIl 2001). To date, sirtuin deacetylases are considered to be an enzyme family that plays an important role in the regulation of cell death and in its life cycle (M. and Chiarugi A., Tr ends Pharmacol ScL, 2005) . The present invention relates to a cosmetic or pharmaceutical composition containing, in a cosmetically or pharmaceutically acceptable medium, at least one compound capable of activating the synthesis of SIRT proteins in the cells of the skin. Preferably, according to the invention, the compounds will activate a particular class of SIRT proteins, SIRT1 proteins. To date, no use of synthetic inducing compounds of SIRT family proteins in skin cells has been described.
Par composé susceptible d'activer la synthèse des protéines SIRT dans les cellules de la peau, on entend essentiellement désigner tous les composés susceptibles de favoriser la production endogène des protéines SIRT ; et tout particulièrement les molécules impliquées dans le contrôle positif des précurseurs tels que l' ADN ou l' ARN.By compound capable of activating the synthesis of SIRT proteins in the cells of the skin is meant essentially all compounds capable of promoting the endogenous production of SIRT proteins; and most particularly the molecules involved in the positive control of precursors such as DNA or RNA.
Parmi ces composés susceptibles d'activer la synthèse des protéines SIRT de la peau, on peut citer différentes molécules dont, par exemple, les polyphénols. Plus particulièrement, on peut citer : des dérivés de trans-stilbène (resveratrol, piceatannol), des dérivés des chalcones (isoliquiritigenine, butéine), les dérivés de flavones (fisteine, luteoline, quercetine).Among these compounds capable of activating the synthesis of SIRT proteins in the skin, mention may be made of various molecules including, for example, polyphenols. More particularly, mention may be made of: trans-stilbene derivatives (resveratrol, piceatannol), chalcone derivatives (isoliquiritigenin, butene), flavone derivatives (fisteine, luteoline, quercetin).
Préférentiellement selon l'invention, les composés, susceptibles de favoriser la synthèse des protéines SIRT dans les cellules de la peau, seront des composés de nature peptidique.Preferably, according to the invention, the compounds capable of promoting the synthesis of SIRT proteins in the cells of the skin will be compounds of a peptide nature.
Parmi les composés de nature peptidique, on peut citer des fragments de protéines, des fragments peptidiques ou polypeptidiques, des peptides et tout enchaînement de deux ou plusieurs acides aminés liés entre eux par des liaisons peptidiques. Préférentiellement selon la présente invention, lesdits fragments peptidiques sont des fragments peptidiques dont le nombre d'acides aminés est compris entre 3 et 50, plus particulièrement entre 3 et 10. Tous ces fragments peptidiques possèdent une activité biologique.Among the compounds of peptide nature, mention may be made of protein fragments, peptide or polypeptide fragments, peptides and any sequence of two or more amino acids linked together by peptide bonds. Preferably, according to the present invention, said peptide fragments are peptide fragments whose number of amino acids is between 3 and 50, more particularly between 3 and 10. All these peptide fragments have a biological activity.
Selon une méthode particulièrement avantageuse de réalisation de l'invention, le composé, susceptible d'activer la synthèse des protéines SIRT de la peau, est un peptide de formule (I) :According to a particularly advantageous method of carrying out the invention, the compound capable of activating the synthesis of the SIRT proteins of the skin is a peptide of formula (I):
(I) (AA)n - Thr - GIn - Asn - Ile - Asp - Thr - Leu - (AA)n dans laquelle (AA) est un acide aminé quelconque, ou un de ses dérivés, et n est un entier compris entre 0 et 3.(I) (AA) n - Thr - GIn - Asn - Ile - Asp - Thr - Leu - (AA) n wherein (AA) is any amino acid, or a derivative thereof, and n is an integer between 0 and 3.
Par ailleurs, selon une méthode de réalisation de l'invention toute particulièrement préférée, le composé, inducteur de protéines SIRT de la peau, possède la séquence Thr - GIn - Asn - Ile - Asp - Thr - Leu.Moreover, according to a very particularly preferred embodiment of the invention, the compound, a SIRT protein inducer of the skin, possesses the Thr-GIn-Asn-Ile-Asp-Thr-Leu sequence.
Par l'expression « les protéines SIRT de la peau », on entend toutes les protéines de la familles SIRT mais, préférentiellement, on entend désigner les protéines SIRTl.By the expression "SIRT proteins of the skin" is meant all the proteins of the SIRT family, but preferentially, the term SIRT1 proteins is meant.
L'invention concerne aussi des formes variantes de ces séquences et/ou de ces fragments. Le terme « variant » désigne ici un polypeptide ou un peptide qui diffère, par exemple, de la séquence d'un peptide de référence tout en conservant ses propriétés essentielles. Généralement, les différences sont limitées de manière à ce que les séquences du peptide de référence et celles du variant soient assez similaires et, dans certaines régions, identiques. Un peptide variant et un peptide de référence peuvent ainsi différer de la séquence d'acides aminés par une ou plusieurs substitutions, additions, délétions dans toutes les combinaisons. Préférentiellement les formes variantes sont celles qui varient des séquences de référence, par la substitution d'acides aminés chimiquement équivalentsThe invention also relates to variant forms of these sequences and / or fragments. The term "variant" herein refers to a polypeptide or peptide that differs from, for example, the sequence of a reference peptide while retaining its essential properties. Generally, the differences are limited so that the sequences of the reference peptide and those of the variant are quite similar and, in some regions, identical. A variant peptide and a reference peptide may thus differ from the amino acid sequence by one or more substitutions, additions, deletions in all combinations. Preferentially, the variant forms are those which vary from the reference sequences, by the substitution of chemically equivalent amino acids
(ou homologues), c'est-à-dire par la substitution d'un résidu par un autre possédant les mêmes caractéristiques. Ainsi, les substitutions classiques se font entre AIa, Val, Leu et Ile ; entre Ser et Thr ; entre les résidus acides Asp et Glu ; entre Asn et GIn ; et entre les résidus basiques Lys et Arg ; ou entre les résidus aromatiques Phe et Tyr.(or homologues), that is to say by the substitution of a residue by another having the same characteristics. Thus, the classical substitutions are between Ala, Val, Leu and Ile; between Ser and Thr; between Asp and Glu acid residues; between Asn and GIn; and between the basic residues Lys and Arg; or between the aromatic residues Phe and Tyr.
Dans l'invention, le terme "acide aminé" se réfère ici à tout acide organique naturel ou non naturel ayant la formule :In the invention, the term "amino acid" refers herein to any natural or unnatural organic acid having the formula:
-NHR-CR-C(O)-O- où chaque -R est indépendamment sélectionné entre un hydrogène et un groupement alkyl ayant entre 1 et 12 atomes de carbone. Préférentiellement, au moins un groupement -R de chaque acide aminé est un hydrogène. Par le terme "alkyl", on entend ici une chaîne carbonée pouvant être linéaire ou ramifiée, substituée (mono- ou poly-) ou non-substituée ; saturée, mono-saturée (une double ou triple liaison dans la chaîne) ou poly-insaturée (deux ou plusieurs doubles liaisons, deux ou plusieurs triples liaisons, une ou plusieurs doubles liaisons et une ou plusieurs triples liaisons dans la chaîne).-NHR-CR-C (O) -O- where each -R is independently selected from hydrogen and an alkyl group having 1 to 12 carbon atoms. Preferably, at least one -R group of each amino acid is a hydrogen. By the term "alkyl" is meant herein a carbon chain which may be linear or branched, substituted (mono- or poly-) or unsubstituted ; saturated, mono-saturated (a double or triple bond in the chain) or polyunsaturated (two or more double bonds, two or more triple bonds, one or more double bonds and one or more triple bonds in the chain).
Le terme « peptide » désigne un enchaînement de deux ou plusieurs acides aminés liés entre eux par des liaisons peptidiques ou par des liaisons peptidiques modifiées ; un polypeptide désignant un peptide de taille plus importante. Par peptide, il faut entendre le peptide naturel ou synthétique de l'invention tel que décrit ci-dessus ou au moins l'un de ses fragments, qu'il soit obtenu par protéolyse ou de manière synthétique ou encore tout peptide naturel ou synthétique dont la séquence est totalement ou partiellement constituée par la séquence du peptide précédemment décrit.The term "peptide" refers to a sequence of two or more amino acids linked together by peptide bonds or modified peptide bonds; a polypeptide designating a larger peptide. By peptide is meant the natural or synthetic peptide of the invention as described above or at least one of its fragments, whether obtained by proteolysis or synthetically or any natural or synthetic peptide which the sequence is totally or partially constituted by the sequence of the peptide previously described.
Il se peut que pour des questions de résistance à la dégradation, il soit nécessaire d'utiliser une forme protégée du peptide selon l'invention. La forme de protection doit évidemment être une forme biologiquement compatible et doit être compatible avec une utilisation dans le domaine des cosmétiques ou de la pharmacie. De nombreuses formes de protection biologiquement compatibles peuvent être envisagées, elles sont bien connues de l'homme du métier comme, par exemple, l'acylation ou l'acétylation de l'extrémité amino-terminale, ou l'amidation ou l'estérification de l'extrémité carboxy-terminale. Ainsi, l'invention concerne une utilisation telle que définie précédemment caractérisée par le fait que le peptide est sous forme protégée ou non. De préférence, on utilise une protection basée soit sur l'acylation ou l'acétylation de l'extrémité amino-terminale, soit sur l'amidation ou l'estérification de l'extrémité carboxy- terminale, soit encore des deux. Les dérivés d'acides aminés et les dérivés de peptides concernent aussi les acides aminés et les peptides reliés entre eux par une liaison pseudo- peptidique. On entend par "liaison pseudo-peptidique" tous les types de liaisons susceptibles de remplacer les liaisons peptidiques "classiques".It may be that for resistance to degradation, it is necessary to use a protected form of the peptide according to the invention. The form of protection must obviously be a biologically compatible form and must be compatible with use in the field of cosmetics or pharmacy. Many biologically compatible forms of protection can be envisaged, they are well known to those skilled in the art such as, for example, the acylation or acetylation of the amino-terminal end, or the amidation or esterification of the carboxy-terminal end. Thus, the invention relates to a use as defined above characterized in that the peptide is in protected form or not. Preferably, protection based on either acylation or acetylation of the amino-terminus, or amidation or esterification of the carboxy terminus, or both is used. The amino acid derivatives and the peptide derivatives also relate to amino acids and peptides linked together by a pseudo-peptide bond. The term "pseudo-peptide bond" means all types of bonds likely to replace the "conventional" peptide bonds.
Dans le domaine des acides aminés, la géométrie des molécules est telle qu'elles peuvent théoriquement se présenter sous la forme d'isomères optiques différents. Il existe, en effet, une conformation moléculaire de l'acide aminé (AA) telle qu'elle dévie à droite le plan de polarisation de la lumière (conformation dextrogyre ou D-aa), et une conformation moléculaire de l'acide aminé (aa) telle qu'elle dévie à gauche le plan de polarisation de la lumière (conformation lévogyre ou L-aa). La nature n'a retenu pour les acides aminés naturels que la conformation lévogyre. En conséquence, un peptide d'origine naturelle ne sera constitué que d'acides aminés de type L-aa. Cependant la synthèse chimique en laboratoire permet de préparer des acides aminés ayant les deux conformations possibles. A partir de ce matériel de base, il est ainsi possible d'incorporer lors de la synthèse de peptide aussi bien des acides aminés sous forme d'isomères optiques dextrogyre ou lévogyre. Ainsi, les acides aminés constituant le peptide selon l'invention peuvent être sous configuration L- et D- ; de manière préférentielle, les acides aminés sont sous forme L. Le peptide selon l'invention peut donc être sous forme L-, D- ou DL-.In the field of amino acids, the geometry of the molecules is such that they can theoretically be in the form of different optical isomers. There is, indeed, a molecular conformation of the amino acid (AA) as it deviates on the right the plane of polarization of the light (dextrorotatory conformation or D-aa), and a molecular conformation of the amino acid ( aa) as it deviates on the left the plane of polarization of the light (laevorotatory conformation or L-aa). Nature has retained for natural amino acids only the levorotatory conformation. Consequently, a peptide of natural origin will consist only of amino acids of the L-aa type. However, chemical synthesis laboratory makes it possible to prepare amino acids having both possible conformations. From this basic material, it is thus possible to incorporate during the synthesis of peptide both amino acids in the form of optical isomers dextrorotatory or levorotatory. Thus, the amino acids constituting the peptide according to the invention can be in L- and D- configuration; preferably, the amino acids are in L form. The peptide according to the invention can therefore be in L-, D- or DL- form.
Les peptides selon l'invention peuvent être préparés par toutes méthodes appropriées, ainsi les peptides peuvent être des peptides isolés à partir de peptides et de protéines existant naturellement, des peptides recombinants, des peptides de synthèse, ou encore des peptides produits par une combinaison de ces méthodes. Bien entendu, les méthodes afin de préparer les peptides selon l'invention sont bien connues de l'homme du métier. Ainsi, le peptide selon l'invention peut être un peptide d'origine naturelle ou synthétique. Préférentiellement selon l'invention, le peptide est obtenu par synthèse chimique.The peptides according to the invention can be prepared by any appropriate method, thus the peptides can be peptides isolated from naturally occurring peptides and proteins, recombinant peptides, synthetic peptides, or peptides produced by a combination of these methods. Of course, the methods for preparing the peptides according to the invention are well known to those skilled in the art. Thus, the peptide according to the invention may be a peptide of natural or synthetic origin. Preferably according to the invention, the peptide is obtained by chemical synthesis.
Il est bien entendu évident que les composés susceptibles d'activer la synthèse des protéines SIRT dans les cellules de la peau pourront être utilisés seuls ou bien en association avec au moins un autre agent actif, dans ou pour la préparation d'une composition cosmétique et/ou dermatologique et/ou pharmaceutique.It is of course obvious that compounds capable of activating the synthesis of SIRT proteins in skin cells may be used alone or in combination with at least one other active agent, in or for the preparation of a cosmetic composition and or dermatological and / or pharmaceutical.
Selon un mode de réalisation avantageux de l'invention, les composés précités, selon l'invention, sont préalablement solubilisés dans un ou plusieurs solvants cosmétiquement ou pharmaceutiquement acceptables, classiquement utilisés par l'homme du métier, comme l'eau, l'éthanol, le propylène glycol, le butylène glycol, le dipropylène glycol, les diglycols éthoxylés ou propoxylés, les polyols cycliques, la vaseline, une huile végétale ou tout mélange de ces solvants.According to an advantageous embodiment of the invention, the abovementioned compounds, according to the invention, are previously solubilized in one or more cosmetically or pharmaceutically acceptable solvents, conventionally used by those skilled in the art, such as water or ethanol. propylene glycol, butylene glycol, dipropylene glycol, ethoxylated or propoxylated diglycols, cyclic polyols, petroleum jelly, a vegetable oil or any mixture of these solvents.
Selon encore un autre mode de réalisation avantageux de l'invention, les composés précités sont préalablement solubilisés dans un vecteur cosmétique ou pharmaceutique comme les liposomes ou adsorbés sur des polymères organiques poudreux, des supports minéraux comme les talcs et bentonites, et plus généralement solubilisés dans, ou fixés sur, tout vecteur cosmétiquement ou pharmaceutiquement acceptable.According to yet another advantageous embodiment of the invention, the abovementioned compounds are first solubilized in a cosmetic or pharmaceutical vector such as liposomes or adsorbed on powdery organic polymers, mineral supports such as talcs and bentonites, and more generally solubilized in or attached to any cosmetically or pharmaceutically acceptable carrier.
La composition, contenant les composés susceptibles d'activer la synthèse des protéines SIRT dans les cellules de la peau, peut être une composition dermatologique ou pharmaceutique ou cosmétique.The composition, containing compounds capable of activating the synthesis of SIRT proteins in skin cells, can be a dermatological or pharmaceutical or cosmetic composition.
La composition selon l'invention est préférentiellement une composition cosmétique et/ou dermatologique dont les excipients sont adaptés à une administration par voie topique externe ; cette composition comprenant avantageusement un milieu cosmétiquement ou pharmaceutiquement acceptable. Préférentiellement selon l'invention, la composition est une composition cosmétique, car elle est destinée à améliorer l'aspect et les performances cutanées générales de l'individu qui en fait usage.The composition according to the invention is preferably a cosmetic and / or dermatological composition, the excipients of which are suitable for administration by the route external topical; this composition advantageously comprising a cosmetically or pharmaceutically acceptable medium. Preferably, according to the invention, the composition is a cosmetic composition, because it is intended to improve the appearance and general cutaneous performance of the individual who makes use of it.
La quantité efficace de principe actif correspond à la quantité nécessaire afin d'obtenir Ie résultat désiré. Selon un mode de réalisation de l'invention, les composés précités sont présents dans les compositions de l'invention en une quantité représentant entre 10"6 et 20 o %, environ, et préférentiellement en une quantité représentant entre 10 ,-4 et 5 % environ par rapport au poids total de la composition finale. Selon un mode de réalisation actuellement préféré, lorsque le composé précité est de nature peptidique, le peptide sera présent dans les compositions de l'invention à une concentration comprise entre 0,005 et 500 ppm (parties par million) environ, et préférentiellement à une concentration comprise entre 0,1 et 50 ppm environ par rapport au poids total de la composition finale. Quelle que soit la forme de l'invention, la composition selon l'invention peut être injectée ou appliquée sur la peau (sur toute zone cutanée du corps), les cheveux, les ongles ou les muqueuses. Selon le mode d'administration, la composition selon l'invention peut se présenter sous toutes les formes galéniques normalement utilisées.The effective amount of active ingredient is the amount needed to achieve the desired result. According to one embodiment of the invention, the abovementioned compounds are present in the compositions of the invention in an amount representing between 10 -6 and 20%, approximately, and preferentially in an amount representing between 10 -4 and 5 About one percent of the total weight of the final composition According to a presently preferred embodiment, when the above-mentioned compound is peptide in nature, the peptide will be present in the compositions of the invention at a concentration of between 0.005 and 500 ppm ( parts per million), and preferably at a concentration of between 0.1 and 50 ppm approximately relative to the total weight of the final composition, whatever the form of the invention, the composition according to the invention can be injected or applied to the skin (on any cutaneous zone of the body), the hair, the nails or the mucous membranes Depending on the method of administration, the composition according to the invention may be s all galenic forms normally used.
Préférentiellement, les compositions selon la présente invention se présenteront sous une forme galénique adaptée à l'administration par voie topique cutanée, et couvrent toutes les formes cosmétiques ou dermatologiques. Ces compositions doivent donc contenir un milieu cosmétiquement acceptable, c'est-à-dire compatible avec la peau, les muqueuses et les phanères.Preferably, the compositions according to the present invention will be in a dosage form suitable for topical administration to the skin, and cover all cosmetic or dermatological forms. These compositions must therefore contain a cosmetically acceptable medium, that is to say, compatible with the skin, mucous membranes and integuments.
Ces compositions pourront notamment se présenter sous forme d'une solution aqueuse, hydroalcoolique ou huileuse ; d'une émulsion huile-dans-eau, eau-dans-huile ou émulsions multiples ; elles peuvent aussi se présenter sous forme de crèmes, de suspensions, ou encore de poudres, adaptées à une application sur la peau, les muqueuses, les lèvres et/ou les phanères. Ces compositions peuvent être plus ou moins fluides et avoir l'aspect d'une crème, d'une lotion, d'un lait, d'un sérum, d'une pommade, d'un gel, d'une pâte ou d'une mousse. Elles peuvent aussi se présenter sous forme solide, comme un stick ou être appliquées sur la peau sous forme d'aérosol. Elles peuvent être utilisées comme produit de soin et/ou comme produit de maquillage de la peau. Ces compositions comprennent, en outre, tout additif communément utilisé dans le domaine d'application envisagé ainsi que les adjuvants nécessaires à leur formulation, tels que des solvants, des épaississants, des diluants, des anti-oxydants, des colorants, des filtres solaires, des agents auto-bronzants, des pigments, des charges, des conservateurs, des parfums, des absorbeurs d'odeur, des actifs cosmétiques ou pharmaceutiques, des huiles essentielles, des vitamines, des acides gras essentiels, des tensioactifs, des polymères filmogènes, etc.These compositions may especially be in the form of an aqueous solution, hydroalcoholic or oily; an oil-in-water, water-in-oil emulsion or multiple emulsions; they may also be in the form of creams, suspensions or powders, suitable for application to the skin, mucous membranes, lips and / or integuments. These compositions may be more or less fluid and have the appearance of a cream, lotion, milk, serum, ointment, gel, paste or paste. a foam. They can also be in solid form, as a stick or be applied to the skin in aerosol form. They can be used as a care product and / or as a make-up product for the skin. These compositions additionally comprise any additive commonly used in the field of application envisaged as well as the adjuvants necessary for their formulation, such as solvents, thickeners, diluents, antioxidants, dyes, sunscreens, self-tanning agents, pigments, fillers, preservatives, perfumes, odor absorbers, cosmetic or pharmaceutical active ingredients, essential oils, vitamins, essential fatty acids, surfactants, film-forming polymers, etc. .
Dans tous les cas, l'homme du métier veillera à ce que ces adjuvants ainsi que leurs proportions soient choisis de telle manière à ne pas nuire aux propriétés avantageuses recherchées de la composition selon l'invention. Ces adjuvants peuvent, par exemple, correspondre de 0,01 à 20 % du poids total de la composition. Lorsque la composition de l'invention est une émulsion, la phase grasse peut représenter de 5 à 80 % en poids et de préférence de 5 à 50 % en poids par rapport au poids total de la composition. Les émulsionnants et co-émulsionnants utilisés dans la composition seront choisis parmi ceux classiquement utilisés dans le domaine considéré. Par exemple, ils peuvent être utilisés en une proportion allant de 0,3 à 30 % en poids, par rapport au poids total de la composition.In all cases, those skilled in the art will ensure that these adjuvants and their proportions are chosen in such a way as not to harm the desirable advantageous properties of the composition according to the invention. These adjuvants may, for example, correspond to 0.01 to 20% of the total weight of the composition. When the composition of the invention is an emulsion, the fatty phase may represent from 5 to 80% by weight and preferably from 5 to 50% by weight relative to the total weight of the composition. The emulsifiers and co-emulsifiers used in the composition will be chosen from those conventionally used in the field under consideration. For example, they can be used in a proportion ranging from 0.3 to 30% by weight, relative to the total weight of the composition.
Bien entendu, l'homme du métier veillera à choisir les éventuels composés complémentaires, actifs ou non-actifs, et/ou leurs quantités, de telle sorte que les propriétés avantageuses du mélange ne soient pas, ou sensiblement pas, altérées par l'adjonction envisagée.Of course, those skilled in the art will take care to choose any additional compounds, active or non-active, and / or their amounts, so that the advantageous properties of the mixture are not, or not substantially, altered by the addition considered.
Les compositions selon l'invention trouvent une application notamment comme compositions cosmétiques ou pharmaceutiques pour la peau, les muqueuses et/ou les semi-muqueuses. Elles trouvent une application en tant que produit de protection et/ou de soin de la peau, ou encore en tant que composition anti-rides et/ou anti-âge. On peut également envisager d'autres applications dans le domaine des compositions en association, par exemple, avec d'autres agents actifs. On peut également utiliser les composés selon l'invention dans des compositions cosmétiques pour l'hygiène corporelle et capillaire.The compositions according to the invention find an application in particular as cosmetic or pharmaceutical compositions for the skin, mucous membranes and / or semi-mucous membranes. They find application as a protection product and / or skincare, or as an anti-wrinkle and / or anti-aging composition. It is also possible to envisage other applications in the field of compositions in combination, for example with other active agents. The compounds according to the invention can also be used in cosmetic compositions for body and hair hygiene.
La récente découverte de la présence des protéines SIRT dans les cellules de la peau, et plus précisément de la présence de la protéine SIRTl, ainsi que leur implication dans de nombreux mécanismes cellulaires fondamentaux et, notamment, ceux impliqués dans le stress cellulaire, ont permis d'envisager de multiples utilisations pour les composés selon l'invention. La protéine SIRTl occupe une fonction très importante dans le vieillissement et la protection cellulaire. En effet, il a été démontré qu'une augmentation de son expression permet à la peau de mieux résister au stress qui l'entoure, c'est-à-dire de mieux lutter contre les phénomènes d'oxydation et, plus généralement, de mieux lutter contre le vieillissement. Plus globalement, l'induction de l'expression de cette protéine dans les cellules de la peau apporte une amélioration générale des mécanismes de protection cellulaire et permettrait d'augmenter la durée de vie cellulaire.The recent discovery of the presence of SIRT proteins in skin cells, and more specifically the presence of the SIRT1 protein, as well as their involvement in many fundamental cellular mechanisms and, in particular, those involved in cellular stress, have allowed to consider multiple uses for compounds according to the invention. SIRT1 protein has a very important function in aging and cellular protection. Indeed, it has been shown that an increase in its expression allows the skin to better withstand the stress that surrounds it, that is to say to better fight against the phenomena of oxidation and, more generally, of better fight against aging. More generally, the induction of the expression of this protein in skin cells provides a general improvement of cell protection mechanisms and would increase the cell life.
Plusieurs utilisations des composés précédemment définis, destinés à activer la synthèse endogène des protéines SIRT, notamment des protéines SIRTl, ou de compositions en contenant, ont donc été envisagés. Ainsi un aspect essentiel de l'invention est l'utilisation d'au moins un composé inducteur de la synthèse endogène des protéines SIRT dans les cellules de la peau, dans ou pour la préparation d'une composition cosmétique et/ou pharmaceutique, le composé ou la composition le contenant étant destinés à apporter des soins à la peau et/ou aux phanères. Plus précisément parmi les composés inducteurs de la synthèse endogène des protéinesSeveral uses of the previously defined compounds intended to activate the endogenous synthesis of SIRT proteins, in particular SIRT1 proteins, or compositions containing them, have therefore been envisaged. Thus, an essential aspect of the invention is the use of at least one inducing compound for the endogenous synthesis of SIRT proteins in skin cells, in or for the preparation of a cosmetic and / or pharmaceutical composition, the compound or the composition containing it being intended to provide care to the skin and / or integuments. More precisely among the compounds inducing the endogenous synthesis of proteins
SIRT5 on peut citer les composés de nature peptidique. Préférentiellement, les composés susceptibles de favoriser la synthèse des protéines SIRT, et plus particulièrement des protéines SIRTl, seront des peptides correspondants à la formule (I). Selon une méthode de réalisation actuellement préférée, le composé, inducteur de protéines SIRT de la peau, possède la séquence Thr - GIn - Asn - Ile - Asp - Thr - Leu.SIRT 5 may be compounds of peptide nature. Preferentially, the compounds capable of promoting the synthesis of SIRT proteins, and more particularly of SIRT1 proteins, will be peptides corresponding to formula (I). According to a currently preferred embodiment, the SIRT protein inducing compound of the skin has the Thr - GIn - Asn - Ile - Asp - Thr - Leu sequence.
Lesdits composés étant aussi avantageusement utilisés afin de lutter de manière curative et/ou préventive contre les manifestations du vieillissement cutané, mais aussi afin d'améliorer l'aspect de la peau et/ou des phanères.Said compounds being also advantageously used in order to fight in a curative and / or preventive manner against the manifestations of skin aging, but also in order to improve the appearance of the skin and / or integuments.
Par les soins de la peau et/ou des phanères, on entend toutes les actions destinées à conserver ou à rétablir un bon fonctionnement de la peau et/ou des phanères ou encore tout moyen qui sert à préserver ou à améliorer leur apparence et/ou leur aspect. Ainsi le soin inclut l'hydratation, l'apaisement, la protection contre tous types d'agression, notamment la protection solaire, la lutte et la prévention des manifestations du vieillissement. Par manifestations cutanées du vieillissement on entend toutes modifications de l'aspect extérieur de la peau dues au vieillissement comme, par exemple, les rides et ridules, la peau flétrie, la peau molle, la peau amincie, le manque d'élasticité et/ou de tonus de la peau, la peau terne et sans éclat mais également toutes modifications internes de la peau qui ne se traduisent pas systématiquement par un aspect extérieur modifié comme, par exemple, toutes dégradations internes de la peau consécutives à une exposition aux rayonnements ultra-violets. Par l'expression "améliorer l'aspect de la peau", on entend tous les phénomènes qui sont susceptibles d'avoir pour conséquence une amélioration visuelle de l'état de la peau. La peau présentera une meilleure apparence ; elle sera, par exemple, beaucoup plus belle, ferme et/ou lisse. Toutes les petites imperfections seront diminuées ou supprimées. L'aspect papyracé de la peau sera, par exemple, atténué.By the care of the skin and / or integuments, we mean all the actions intended to maintain or restore a good functioning of the skin and / or superficial body growths or any means which serves to preserve or improve their appearance and / or their appearance. So the care includes hydration, soothing, protection against all types of aggression, including sun protection, the fight and the prevention of the manifestations of aging. By cutaneous manifestations of aging is meant any changes in the external appearance of the skin due to aging, such as, for example, wrinkles and fine lines, wilted skin, soft skin, thinned skin, lack of elasticity and / or skin tone, dull and lackluster skin but also any internal changes in the skin that do not always translate into an external appearance modified, for example, any internal skin damage resulting from exposure to ultraviolet radiation. The term "improve the appearance of the skin" means all phenomena that are likely to result in a visual improvement of the state of the skin. The skin will look better; it will be, for example, much more beautiful, firm and / or smooth. All small imperfections will be diminished or removed. The papery appearance of the skin will, for example, be attenuated.
De plus, le principe actif selon l'invention, ou la composition le contenant, peuvent être destinés à protéger les substrats kératiniques, et plus particulièrement à protéger la peau et/ou les phanères contre tous les types d'agressions extérieures. L'utilisation de ces agents actifs, ou d'une composition les contenant, va permettre aux substrats kératiniques d'être protégés et de mieux résister au stress que produit sur eux l'environnement. On entend par le terme "agression extérieure" les agressions que peut produire l'environnement. Ces agressions peuvent être d'origine chimique, physique, biologique ou thermique. Selon un autre aspect, les composés seront avantageusement utilisés afin de diminuer et/ou de prévenir les réactions inflammatoires et/ou irritantes cutanées. En effet, les composés selon l'invention, destinés à activer la synthèse endogène des protéines SIRTl, ont des effets anti-inflammatoires et anti-irritants. L'utilisation des propriétés de ces actifs permet donc d'avoir une peau plus protégée et nettement moins sensible aux diverses agressions qu'elle peut rencontrer. La peau est ainsi apaisée.In addition, the active ingredient according to the invention, or the composition containing it, may be intended to protect keratinous substrates, and more particularly to protect the skin and / or integuments against all types of external aggression. The use of these active agents, or a composition containing them, will allow the keratinous substrates to be protected and to better withstand the stress that the environment produces on them. The term "external aggression" is understood to mean the aggressions that the environment can produce. These attacks can be of chemical, physical, biological or thermal origin. In another aspect, the compounds will be advantageously used to reduce and / or prevent inflammatory and / or skin irritant reactions. Indeed, the compounds according to the invention, intended to activate the endogenous synthesis of SIRT1 proteins, have anti-inflammatory and anti-irritant effects. The use of the properties of these assets therefore makes it possible to have a skin that is more protected and much less sensitive to the various aggressions that it may encounter. The skin is soothed.
Par ailleurs, les composés selon l'invention tels que définis précédemment, stimulent le fonctionnement métabolique des cellules de la peau. Ils permettent ainsi d'augmenter la synthèse de protéines essentielles à son fonctionnement, notamment en augmentant la synthèse de protéines constitutives de la matrice extra-cellulaire. Les composés selon l'invention, ou la composition les contenant, possèdent ainsi une action positive sur la régénération tissulaire. Les composés selon l'invention sont tout particulièrement efficaces afin de traiter les troubles de la cicatrisation.Moreover, the compounds according to the invention as defined above, stimulate the metabolic functioning of the cells of the skin. They thus make it possible to increase the synthesis of proteins essential to its functioning, in particular by increasing the synthesis of proteins constituting the extracellular matrix. The compounds according to the invention, or the composition containing them, thus have a positive action on tissue regeneration. The compounds according to the invention are particularly effective in treating cicatrization disorders.
Ces composés, destinés à activer la synthèse endogène des protéines SIRT, précédemment définie, sont ainsi utilisés dans ou pour la fabrication d'une composition pharmaceutique et/ou cosmétique, à usage topique. Ils seront utilisés, d'une manière plus générale, afin de traiter des affections dermatologiques.These compounds, intended to activate the endogenous synthesis of SIRT proteins, previously defined, are thus used in or for the manufacture of a pharmaceutical and / or cosmetic composition, for topical use. They will be used, more generally, to treat dermatological conditions.
Par affections dermatologiques, on entend toutes les maladies affectant la peau et ayant ou non des conséquences visibles. A ce titre, on peut citer par exemple : des désordres liés à des problèmes de différenciations et de proliférations cellulaires, des problèmes liés à la kératinisation, des troubles inflammatoires ou allergiques, des troubles liés aux fonctions sébacées, des proliférations dermiques ou épidermiques (bénignes ou malignes) ; des désordres cutanés dus à une exposition aux rayonnements U.V., des pathologies associées au vieillissement chronologique ou actinique.Dermatological conditions are all diseases affecting the skin and having or not visible consequences. As such, for example: disorders related to cell differentiation and proliferation problems, problems with keratinization, inflammatory or allergic disorders, disorders related to sebaceous functions, dermal or epidermal proliferations (benign or malignant); cutaneous disorders due to exposure to UV radiation, pathologies associated with chronological or actinic aging.
Par ailleurs, selon un autre aspect, les composés selon l'invention, tels que décrit précédemment, destinée à activer la synthèse endogène des protéines SIRT dans les cellules de la peau, seront utilisés pour la fabrication d'un médicament destiné au traitement des affections dermiques. La présente invention a également pour objet l'utilisation, à titre de médicament, des composés décrits ci-dessus.Furthermore, according to another aspect, the compounds according to the invention, as described above, intended to activate the endogenous synthesis of SIRT proteins in the cells of the skin, will be used for the manufacture of a medicament intended for the treatment of affections dermal. The present invention also relates to the use, as a medicament, of the compounds described above.
Selon un autre aspect, la présente invention concerne un procédé de traitement cosmétique pour les soins de la peau et/ou des phanères consistant à appliquer sur la surface de la peau une quantité efficace d'agent actif, ou de la composition cosmétique le contenant, telle que définie précédemment, afin d'obtenir l'action désirée. Ces procédés peuvent notamment être utilisés afin de traiter de manière préventive et/ou curative les manifestations du vieillissement cutané, mais aussi afin de protéger la peau et/ou les phanères contre les agressions extérieures telles que les effets néfastes du rayonnement, en particulier des UV, ou encore afin de lutter contre les manifestations de rinflammation et d'irritation cutanée.According to another aspect, the present invention relates to a cosmetic treatment method for care of the skin and / or superficial body growth consisting in applying to the surface of the skin an effective quantity of active agent, or of the cosmetic composition containing it, as defined above, in order to obtain the desired action. These methods may especially be used in order to preventatively and / or curatively treat the manifestations of cutaneous aging, but also in order to protect the skin and / or integuments against external aggressions such as the harmful effects of radiation, in particular UV radiation. or to fight against the manifestations of inflammation and skin irritation.
Le procédé de traitement cosmétique de l'invention peut être mis en œuvre notamment en appliquant les compositions cosmétiques telles que définies ci-dessus, selon la technique d'utilisation habituelle de ces compositions, par exemple : application de crèmes, de gels, de sérums, de lotions, de laits, de shampooings ou de compositions anti- solaires, sur la peau ou sur les cheveux, ou encore application de dentifrice sur les gencives.The cosmetic treatment method of the invention may be implemented in particular by applying the cosmetic compositions as defined above, according to the usual technique of use of these compositions, for example: application of creams, gels, serums , lotions, milks, shampoos or sunscreens, on the skin or on the hair, or application of toothpaste on the gums.
Des modes de réalisation particuliers de ce procédé de traitement cosmétique résultent également de la description précédente. D'autres avantages et caractéristiques de l'invention apparaîtront mieux à la lecture des exemples donnés à titre illustratif et non limitatif.Particular embodiments of this cosmetic treatment method also result from the foregoing description. Other advantages and characteristics of the invention will appear better on reading the examples given by way of illustration and not limitation.
Exemple : Préparation de compositions.Example: Preparation of compositions.
Les quantités indiquées sont données en pourcentage de poids. 1 - Crème de soin anti-rides:The quantities indicated are given as a percentage of weight. 1 - Anti-wrinkle cream:
Figure imgf000013_0001
Figure imgf000014_0001
Figure imgf000013_0001
Figure imgf000014_0001
Les constituants de la phase A et de la phase B sont chauffés séparément à une température comprise entre 65°C et 70°C, la phase C est incorporée, puis la phase A est émulsionnée dans la phase B. Le carbomer est neutralisé avec la phase D à une température aux alentours de 45°C. La phase E est ensuite additionnée sous agitation et le refroidissement est poursuivi jusqu'à 25°C.The constituents of phase A and phase B are heated separately at a temperature between 65 ° C and 70 ° C, phase C is incorporated, then phase A is emulsified in phase B. The carbomer is neutralized with the phase D at a temperature around 45 ° C. Phase E is then added with stirring and cooling is continued to 25 ° C.
2 - Lait corporel anti-âge:2 - Anti-aging body milk:
Figure imgf000014_0002
Figure imgf000014_0002
Figure imgf000015_0001
Figure imgf000015_0001
Les constituants de la phase A et de la phase B sont chauffés séparément à une température comprise entre 70°C et 75°C. La phase B est émulsionnée dans A sous agitation « Staro ». Après un refroidissement jusqu'à 50°C, le mélange est neutralisé avec la phase C. La phase D est ensuite additionnée lorsque la température se situe en dessous de 40°C. Le refroidissement est poursuivi jusqu'à 250C sous agitation lente.The components of phase A and phase B are heated separately at a temperature between 70 ° C and 75 ° C. Phase B is emulsified in A with stirring "Staro". After cooling to 50 ° C, the mixture is neutralized with phase C. Phase D is then added when the temperature is below 40 ° C. Cooling is continued to 25 0 C with slow stirring.
3 - Crème protection solaire:3 - Sun protection cream:
Figure imgf000015_0002
Figure imgf000015_0002
Figure imgf000016_0001
Figure imgf000016_0001
Les constituants de la phase A et de la phase B sont chauffés séparément à une température comprise entre 70°C et 75°C. La phase B est émulsionnée dans A sous agitation. La phase C est ajoutée, à 45 °C, en augmentant l'agitation. La phase D est ensuite additionnée lorsque la température se situe en dessous de 40°C. Le refroidissement est poursuivi jusqu'à 25°C sous vive agitation. The components of phase A and phase B are heated separately at a temperature between 70 ° C and 75 ° C. Phase B is emulsified in A with stirring. Phase C is added at 45 ° C, increasing stirring. Phase D is then added when the temperature is below 40 ° C. Cooling is continued up to 25 ° C with vigorous stirring.

Claims

REVENDICATIONS
1. Composition cosmétique ou pharmaceutique caractérisée en ce qu'elle contient, dans un milieu cosmétiquement ou pharmaceutiquement acceptable, au moins un composé susceptible d'activer la synthèse des protéines SIRT dans les cellules de la peau.1. Cosmetic or pharmaceutical composition characterized in that it contains, in a cosmetically or pharmaceutically acceptable medium, at least one compound capable of activating the synthesis of SIRT proteins in skin cells.
2. Composition selon la revendication 1 caractérisé en ce que les excipients de cette composition sont adaptés à une administration par voie topique externe.2. Composition according to claim 1 characterized in that the excipients of this composition are suitable for external topical administration.
3. Composition selon la revendication 1 ou 2 caractérisée en ce que les protéines SIRT sont des protéines SIRTl.3. Composition according to claim 1 or 2 characterized in that the SIRT proteins are SIRTl proteins.
4. Composition selon l'une quelconque des revendications précédentes caractérisée en ce que les composés susceptibles d'activer la synthèse des protéines SIRT dans les cellules de la peau sont des composés de nature peptidique..4. Composition according to any one of the preceding claims, characterized in that the compounds capable of activating the synthesis of SIRT proteins in skin cells are compounds of a peptide nature.
5. Composition selon la revendication 4 caractérisée en ce que le composé est un peptide de formule (I) : (I) (AA)n - Thr - GIn - Asn - Ile - Asp - Thr - Leu - (AA)n dans laquelle (AA) est un acide aminé quelconque, ou un de ses dérivés, et n est un entier compris entre 0 et 3.5. Composition according to claim 4, characterized in that the compound is a peptide of formula (I): (I) (AA) n-Thr-GIn-Asn-Ile-Asp-Thr-Leu-(AA) n in which (AA) is any amino acid, or a derivative thereof, and n is an integer of 0 to 3.
6. Composition selon la revendication 4 caractérisée en ce que le peptide possède la séquence Thr - GIn — Asn - Ile - Asp - Thr - Leu.6. Composition according to claim 4 characterized in that the peptide has the sequence Thr - GIn - Asn - Ile - Asp - Thr - Leu.
7. Composition selon l'une quelconque des revendications 1 ou 2 caractérisée en ce que ledit composé, susceptibles d'activer la synthèse des protéines SIRT, est présent en une quantité représentant entre 10"6 et 20 % environ, et préférentiellement en une quantité représentant entre 10"4 et 5 % par rapport au poids total de la composition finale. 7. Composition according to any one of claims 1 or 2 characterized in that said compound, capable of activating the synthesis of SIRT proteins, is present in an amount representing between 10 "6 and 20% approximately, and preferably in a quantity representing between 10 -4 and 5% relative to the total weight of the final composition.
8. Composition selon l'une quelconque des revendications 3 à 6 caractérisée en ce que le composé de nature peptidique est présent, dans la composition, à une concentration comprise entre 0,05 et 500 ppm environ, et préférentiellement à une concentration comprise entre 0,1 et 50 ppm environ par rapport au poids total de la préparation finale.8. Composition according to any one of claims 3 to 6 characterized in that the compound of peptide nature is present in the composition at a concentration between about 0.05 and 500 ppm, and preferably at a concentration between 0 , 1 and 50 ppm about the total weight of the final preparation.
9. Utilisation d'au moins un composé susceptible d'activer la synthèse endogène des protéines SERT dans les cellules de la peau, dans ou pour la préparation d'une composition, le composé ou la composition étant destinés aux soins de la peau et/ou des phanères.9. Use of at least one compound capable of activating the endogenous synthesis of SERT proteins in skin cells, in or for the preparation of a composition, the compound or the composition being intended for skin care and / or or dander.
10. Utilisation d'au moins un composé susceptible d'activer la synthèse endogène des protéines SIRT dans les cellules de la peau, dans ou pour la préparation d'une composition, le composé ou la composition étant destinés à protéger la peau et/ou les phanères contre tous les types d'agressions extérieures.10. Use of at least one compound capable of activating the endogenous synthesis of SIRT proteins in skin cells, in or for the preparation of a composition, the compound or the composition being intended to protect the skin and / or dermers against all types of external aggression.
11. Utilisation d'au moins un composé susceptible d'activer la synthèse endogène des protéines SERT dans les cellules de la peau, dans ou pour la préparation d'une composition, le composé ou la composition étant destinés à diminuer et/ou à prévenir les réactions inflammatoires et/ou irritantes cutanées11. Use of at least one compound capable of activating the endogenous synthesis of SERT proteins in skin cells, in or for the preparation of a composition, the compound or the composition being intended for reducing and / or preventing inflammatory and / or irritating skin reactions
12. Utilisation d'au moins un composé susceptible d'activer la synthèse endogène des protéines SERT dans les cellules de la peau, pour la fabrication d'un médicament destiné au traitement des affections dermiques.12. Use of at least one compound capable of activating the endogenous synthesis of SERT proteins in skin cells, for the manufacture of a medicament for the treatment of dermal conditions.
13. Utilisation selon l'une quelconque des revendications 9 à 12 caractérisée en ce que les protéines SERT sont des protéines SERTI.13. Use according to any one of claims 9 to 12, characterized in that the SERT proteins are SERTI proteins.
14. Utilisation selon l'une quelconque des revendications 9 à 13 caractérisé en ce que le composé est un peptide de formule (I) :14. Use according to any one of claims 9 to 13 characterized in that the compound is a peptide of formula (I):
(I) (AA)n - Thr - Gm - Asn - Ile - Asp - Thr - Leu - (AA)n dans laquelle (AA) est un acide aminé quelconque, ou un de ses dérivés, et n est un entier compris entre 0 et 3. (I) (AA) n - Thr - Gm - Asn - Ile - Asp - Thr - Leu - (AA) n wherein (AA) is any amino acid, or a derivative thereof, and n is an integer between 0 and 3.
15. Utilisation selon la revendication 14 caractérisé en ce que le peptide possède la séquence Thr - GIn - Asn - Ile - Asp - Thr - Leu.15. Use according to claim 14 characterized in that the peptide has the sequence Thr - GIn - Asn - Ile - Asp - Thr - Leu.
16. Utilisation selon l'une quelconque des revendications 9 à 15 caractérisée en ce que la composition contient des excipients cosmétiquement ou pharmaceutiquement acceptables.16. Use according to any one of claims 9 to 15 characterized in that the composition contains cosmetically or pharmaceutically acceptable excipients.
17. Utilisation selon la revendication 16 caractérisée en ce que les excipients sont adaptés à une administration topique externe.17. Use according to claim 16 characterized in that the excipients are suitable for external topical administration.
18. Procédé de traitement cosmétique de la peau et/ou des phanères, caractérisé par le fait que l'on applique sur la peau et/ou sur les phanères une composition cosmétique telle que définie selon l'une quelconque des revendications 1 à 8. 18. Process for the cosmetic treatment of the skin and / or superficial body growths, characterized in that a cosmetic composition as defined in any one of Claims 1 to 8 is applied to the skin and / or to the integuments.
PCT/FR2006/000699 2005-04-01 2006-03-30 Use of compounds inducing synthesis of sirt proteins in or for preparing a cosmetic or pharmaceutical composition WO2006103356A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0503198 2005-04-01
FR0503198A FR2883751B1 (en) 2005-04-01 2005-04-01 USE OF COMPOUNDS INDUCING THE SYNTHESIS OF SIRT PROTEINS IN OR FOR THE PREPARATION OF A COSMETIC OR PHARMACEUTICAL COMPOSITION

Publications (2)

Publication Number Publication Date
WO2006103356A2 true WO2006103356A2 (en) 2006-10-05
WO2006103356A3 WO2006103356A3 (en) 2007-03-22

Family

ID=35351669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/000699 WO2006103356A2 (en) 2005-04-01 2006-03-30 Use of compounds inducing synthesis of sirt proteins in or for preparing a cosmetic or pharmaceutical composition

Country Status (2)

Country Link
FR (1) FR2883751B1 (en)
WO (1) WO2006103356A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961814B1 (en) 2010-06-29 2014-09-26 Isp Investments Inc NOVEL SIRTUIN 6 ACTIVATOR PEPTIDES AND COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING SAME.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002555A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002555A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PORCU M ET AL: "The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 26, no. 2, février 2005 (2005-02), pages 94-103, XP004727629 ISSN: 0165-6147 *

Also Published As

Publication number Publication date
FR2883751A1 (en) 2006-10-06
FR2883751B1 (en) 2008-04-11
WO2006103356A3 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
EP1490092B1 (en) Cosmetic or pharmaceutical composition containing peptides
FR2883752A1 (en) USE OF COMPOUNDS INDUCING THE SYNTHESIS OF SIRT PROTEINS IN OR FOR THE PREPARATION OF A COSMETIC OR PHARMACEUTICAL COMPOSITION
EP1868632B1 (en) Dermatological and/or cosmetic composition containing proteins of the sirt family
EP2240505B1 (en) Peptide for activating aquaporin synthesis
EP1575605B1 (en) Cosmetic or pharmaceutical composition comprising peptides with the sequence arg-gly-ser
FR2925500A1 (en) New aquaporin peptides useful in cosmetic, nutraceutical and dermatological compositions
EP2086564B1 (en) Peptide-containing pharmaceutical and/or cosmetic composition
WO2006103352A1 (en) Use of compounds inducing synthesis of sirt proteins in or for preparing a cosmetic or pharmaceutical compositions
EP2026879B1 (en) Use of peptides as active slimming ingredients
EP2150267B1 (en) Pharmaceutical and/or cosmetic composition containing a cytochrome c-activating active ingredient
EP2367842B1 (en) Hmg-coa reductase derived peptide and cosmetic or pharmaceutical composition containing same
WO2006103356A2 (en) Use of compounds inducing synthesis of sirt proteins in or for preparing a cosmetic or pharmaceutical composition
FR2904532A1 (en) DERMATOLOGICAL AND / OR COSMETIC COMPOSITION CONTAINING POLYPEPTIDES OR PEPTIDES
EP2370453B1 (en) Peptides derived from hmg-coa reductase and cosmetic and/or pharmaceutical composition containing the same
EP2150266B1 (en) Pharmaceutical and/or cosmetic composition containing an active ingredient which is antioxidant and which activates cell energy
FR2915394A1 (en) PHARMACEUTICAL AND / OR COSMETIC COMPOSITION CONTAINING PEPTIDES
EP2250187B1 (en) Peptide and cosmetic and/or pharmaceutical composition containing the same
WO2010072929A1 (en) Soothing cosmetic or pharmaceutical composition comprising a peptide which activates hmg-coa reductase
WO2010072928A1 (en) Soothing pharmaceutical or cosmetic composition comprising a peptide that activates hmg-coa reductase
WO2008145851A1 (en) Pharmaceutical and/or cosmetic composition containing peptides

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06743630

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6743630

Country of ref document: EP